MannKind shares tumbled more than 8 percent in midday trading April 1, despite an announcement that the company had received the first milestone payment in its deal with United Therapeutics. United paid $12.5 million to Westlake Village-based MannKind for its inhalable dry powder version of United’s high blood pressure therapy treprostinil. The new delivery mechanism…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
